Periotherapia, which is working on antibody drug development for triple-negative breast cancer, has received an additional 400 million yen investment from Mitsubishi UFJ Capital and Osaka University Venture Capital (OUVC).
Summary
Periotherapia secured an additional 400 million yen in investment from Mitsubishi UFJ Capital and Osaka University Venture Capital. The company is developing antibody drugs for triple-negative breast cancer. This funding should help it advance its life sciences drug development work. The article does not mention a software product launch or a people move.
Funding
Amount
$3.5M
Total raised
Date
March 9, 2022
Announcement date
Investors
Mitsubishi UFJ Capital
Lead investors
Company
https://periotherapia.co.jp/
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected